



Article

# Dynamics of the Second Extracellular Loop Control Transducer Coupling of Peptide-Activated GPCRs

Marcel M. Wygas<sup>1</sup>, Jeannette M. Laugwitz<sup>2</sup>, Peter Schmidt<sup>2</sup>, Matthias Elgeti<sup>2,3</sup> and Anette Kaiser<sup>1,4,\*</sup>

<sup>1</sup> Faculty of Life Sciences, Institute of Biochemistry, Leipzig University, Brüderstr. 34, 04103 Leipzig, Germany

<sup>2</sup> Medical Faculty, Institute of Medical Physics and Biophysics, Leipzig University, Haertelstasse 16-18, 04107 Leipzig, Germany

<sup>3</sup> Medical Faculty, Institute for Drug Discovery, Leipzig University, Haertelstasse 16-18, 04107 Leipzig, Germany

<sup>4</sup> Medical Faculty, Department of Anesthesiology and Intensive Care, Leipzig University, Liebigstrasse 19, 04103 Leipzig, Germany

\* Correspondence: anette.kaiser@medizin.uni-leipzig.de

**Abstract:** Many peptide-activated rhodopsin-like GPCRs share a  $\beta$ -hairpin folding motif in the extracellular loop 2 (ECL2), which interacts with the peptide ligand while at the same time being connected to transmembrane helix 3 (TM3) via a highly conserved disulfide bond. Currently, it remains unknown whether the coupling of the specifically shaped ECL2 to TM3 influences the activation of peptide-activated GPCRs. We investigated this possibility in a selection of peptide GPCRs with known structures. Most of the receptors with cysteine to alanine mutations folded like the respective wild-type and resided in the cell membrane, challenging pure folding stabilization by the disulfide bridge. G-protein signaling of the disulfide mutants was retained to a greater extent in secretin-like GPCRs than in rhodopsin-like GPCRs, while recruitment of arrestin was completely abolished in both groups, which may be linked to alterations in ligand residence time. We found a correlation between receptor activity of the neuropeptide Y<sub>2</sub> receptor and alterations in ECL2 dynamics using engineered disulfide bridges or site-directed spin labeling and EPR spectroscopy. These data highlight the functional importance of the TM3-ECL2 link for the activation of specific signaling pathways in peptide-activated GPCRs, which might have implications for future drug discovery.



**Citation:** Wygas, M.M.; Laugwitz, J.M.; Schmidt, P.; Elgeti, M.; Kaiser, A. Dynamics of the Second Extracellular Loop Control Transducer Coupling of Peptide-Activated GPCRs. *Int. J. Mol. Sci.* **2023**, *24*, 12197. <https://doi.org/10.3390/ijms241512197>

Academic Editor: Honoo Satake

Received: 26 June 2023

Revised: 20 July 2023

Accepted: 28 July 2023

Published: 30 July 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Keywords:** peptide G-protein-coupled receptor (GPCR); extracellular loop; conserved disulfide; electron paramagnetic resonance (EPR); functional selectivity; arrestin

## 1. Introduction

G-protein-coupled receptors (GPCRs) form the largest group of transmembrane receptors and are activated by a variety of different ligand classes, including light, small molecules, ions, proteins, or peptides. They are involved in the majority of physiological processes, and thus, it is not surprising that they are targeted by over 30% of all FDA-approved drugs [1,2]. GPCRs share a common overall structure with seven transmembrane helices connected by three extracellular and three intracellular loops. However, they can be sub-classified into five phylogenetic families according to the GRAFS system [3], which display distinct sequence signatures in the transmembrane (TM) domain that correlate with differences in their activation mechanism. Previously, it had been assumed that GPCRs act as simple on/off switches. However, work of the last decade has made increasingly clear that they act as molecular modulators. A detailed look into the well-studied rhodopsin family [4–6], but also secretin-like [7,8] and frizzled receptors [9,10], reveals that GPCRs display high structural plasticity and molecular dynamics. This molecular flexibility not only allows for binding of different ligands but also for the occurrence of ligand-specific con-

formational changes upon receptor activation and, thus, signaling via multiple transducers from a single receptor [11,12].

Many efforts have been undertaken to identify common mechanisms of receptor activation in these families. This led to the discovery of a variety of macro- and microswitches, such as the DRY, NPxxY, or CWxP motifs, that are involved in the maintenance of the inactive state and the activation of rhodopsin-like GPCRs [13,14]. Instead, additional contacts, such as a glycine kink in TM7 or a leucine cluster in TM6, are characteristic for secretin-like GPCRs [13]. Despite the recent advances in the understanding of GPCR structural dynamics, it is noteworthy that most efforts were devoted to the transmembrane region, which generally displays a high sequence homology. In addition, the more diverse extracellular regions may also contribute to receptor activation. In this regard, an extracellular disulfide bond is conserved in many GPCRs (92% in rhodopsin-like GPCRs, 97% in secretin-like GPCRs) across all subclasses and chemical types of ligands [15]. Early on, it has been shown that this disulfide linkage facilitates GPCR folding and enhances ligand binding [16–20]. However, in light of the recent wealth of structural information, we should revisit whether this structural feature has a functional role during GPCR activation. In the present manuscript, we place particular emphasis on pathway-specific effects for different transducers and receptor subfamilies.

One particularly interesting instance are rhodopsin-like peptide-activated GPCRs. In this family, a conserved  $\beta$ -hairpin folding motif can be found in the extracellular loop 2 (ECL2) connected to transmembrane helix 3 via the highly conserved disulfide bond [21]. While in many systems it has been shown that the ECL2 is intimately involved in ligand binding [22–29], the influence of the TM3-ECL2 linkage via the conserved disulfide bond on ligand binding and pathway-specificity remains unclear. The observation of this common structural feature despite the phylogenetically only distant relation of different peptide-activated receptors (in  $\alpha$  through  $\delta$ -branch of the rhodopsin family, respectively) reinforces the idea of extracellular loops participating in domain coupling for GPCR activation [30,31]. We, therefore, hypothesized that the linkage to TM3 and the specifically folded ECL2 is part of a TM-ECL-spanning allosteric network involved in receptor activation that constitutes the bias switch which differently regulates downstream transducer coupling.


In this study, we investigated the effect of mutations of the conserved disulfide bond on expression, trafficking, ligand binding, and transducer coupling for a selection of rhodopsin-like peptide-activated GPCR as well as secretin-like receptors. The loss of the conserved disulfide bond was mostly tolerated during receptor folding. Using the neuropeptide  $Y_2$  receptor ( $Y_2R$ ) as a prototype, we show that specific ECL2 conformations and a level of flexibility are required for function. G protein signaling was generally affected to varying degrees, but arrestin recruitment was abolished in all tested variants, indicating that the conserved disulfide bond is required in a pathway-specific context. In addition, G-protein-coupling was significantly less affected in secretin-like GPCRs, suggesting that other structural elements, such as the N-terminal domain, may stabilize ligand binding and facilitate receptor activation.

## 2. Results

### 2.1. The Conserved Disulfide Controls ECL2 Dynamics and Function of the $Y_2R$

NPY is the most abundant neuropeptide in the brain and is recognized by four GPCRs rendering it an excellent model system for functional regulation [32,33]. CryoEM has recently provided intriguing insights into peptide binding in the neuropeptide Y family [24]. Both structural snapshots and receptor mutagenesis suggest that the ECL2 represents an important epitope for peptide binding and selectivity and is essential for full activity of the receptor [24]. Given the high structural conservation of the two short antiparallel  $\beta$ -strands and their connection to TM3 via a disulfide bridge, we wondered whether the disulfide merely stabilizes the overall fold or if it may specifically contribute to receptor activation by enhancing the allosteric communication to the TM bundle. To probe this, we initially created two variants of the  $Y_2R$  in which each of the cysteines of the conserved disulfide

was individually exchanged for alanine. We expected similar outcomes if the effect was related to the loss of the disulfide, while environmental effects arising from positional mutagenesis could additionally affect a single variant. To our surprise, both Y<sub>2</sub> receptor variants, Y<sub>2</sub>R\_C123<sup>3,25</sup>A and Y<sub>2</sub>R\_C203<sup>45,50</sup>A, folded well and were expressed at the cell membrane at levels comparable to the wild-type receptor (Figure 1A), enabling further investigations of receptor activity.




**Figure 1.** Expression and biological activity of Y<sub>2</sub>R variants with a mutation in the conserved disulfide bridge. (A) Live cell fluorescence microscopy shows a wild-type-like expression pattern of the disulfide bridge deficient variants. Pictures representative of two independent experiments, scale bar equals 10 μm. (B) Both Y<sub>2</sub>R variants showed a similar signaling profile in the native G<sub>i/o</sub> pathway and remained fully activatable with 10 μM NPY. (C) Inositol monophosphate accumulation assay via a chimeric G<sub>qi</sub> confirms the results of the cAMP accumulation assay with wild-type-like maximal activation. (D) Arrestin recruitment was not detectable to C123<sup>3,25</sup>A and C203<sup>45,50</sup>A variants in BRET-based assays, thus indicating an impairment of the arrestin pathway. (E) In NanoBRET-based ligand binding assays, specific binding of K<sup>18</sup>-TAMRA-NPY was not detectable for Y<sub>2</sub>R\_C123<sup>3,25</sup>A and Y<sub>2</sub>R\_C203<sup>45,50</sup>A variants, indicating loss of high affinity and low affinity binding states that are characteristic for the wild-type receptor. Data represent the normalized means ± SEM of  $n \geq 5$  (B),  $n \geq 3$  (C),  $n \geq 2$  (D), and  $n = 4$  (E) independent experiments performed in technical triplicate.

In the G<sub>i</sub> pathway, the variants Y<sub>2</sub>R\_C123<sup>3,25</sup>A and Y<sub>2</sub>R\_C203<sup>45,50</sup>A substantially lost activity and displayed an EC<sub>50</sub> that was shifted around four orders of magnitude compared to the wild-type Y<sub>2</sub>R, but full receptor activation occurred at 10 μM NPY concentration (Figure 1B). This result was confirmed using a chimeric G<sub>qi</sub> protein [34] that redirects signaling from the native G<sub>i</sub> to the G<sub>q</sub> pathway and thus enables the detection of inositol phosphate accumulation (Figure 1C). In this assay setting, the EC<sub>50</sub> of the disulfide mutants was shifted similarly for both mutants, which indicates that the severe reduction of receptor activity can be attributed to the lack of the disulfide linkage as such and not to the individual mutations.

In order to test for possible pathway specificity, we examined the recruitment of arrestin3 to the Y<sub>2</sub>R and its variants via a BRET-based arrestin recruitment assay. We titrated the receptor-to-arrestin ratios to ensure donor saturation (see Methods for details). Under these conditions, NPY induced arrestin recruitment to wild-type Y<sub>2</sub>R with an EC<sub>50</sub> of 96 nM, but no arrestin recruitment was detectable in the disulfide bridge deficient C123<sup>3,25</sup>A and C203<sup>45,50</sup>A variants at 10 μM NPY after 10 min, indicating an >100-fold impairment in the arrestin pathway (Figure 1D). Collectively, the signaling data indicated that the removal of the conserved disulfide bond profoundly disturbed the signaling of the Y<sub>2</sub>R, which was not caused by changes in membrane expression.

Next, we checked whether these signaling deficits were due to deficits in receptor activation or if ligand binding was also compromised. To this end, we performed NanoBRET-based ligand binding assays using a genetic fusion of a nanoluciferase to the N-terminus of the receptor and a tetramethylrhodamine (TAMRA)-labeled peptide ligand. To correct for unspecific binding, we subtracted the BRET values obtained in the presence of 30 μM of the unlabeled peptide NPY or the high-affinity Y<sub>2</sub>R antagonist JNJ-31020028 [23,35]. The wild-type receptor displayed a biphasic binding behavior showing a high-affinity state with an K<sub>d</sub> of 2.3 nM, which represents the G-protein-bound active signaling state, as well as a low-affinity state with an K<sub>d</sub> of 267 nM, which was attributed to transducer-free binding states [24]. In contrast to the observations in the wild-type, high- and low-affinity binding were abolished in the disulfide bridge deficient C123<sup>3,25</sup>A and C203<sup>45,50</sup>A variants, which indicated a severe loss of binding beyond levels that are detectable in our assay setting (Figure 1E).

Based on this observation, we hypothesized that the removal of the structural constraint might have resulted in a changed conformation of the ECL2, leading to the observed effects on ligand binding and receptor signaling. We reasoned that the ECL2 might become highly flexible, rapidly fluctuating between multiple conformations; alternatively, the lack of covalent contacts with TM3 might lead to a collapse of the loop conformation and stable occlusion of the TM binding pocket. To answer this question, we employed continuous wave electron paramagnetic resonance spectroscopy (CW-EPR) and site-directed spin labeling [36] as a highly sensitive reporter of local structure and dynamics [37]. We chose position A202<sup>45,49</sup> as the spin labeling site, which is located in the ECL2 directly next to the disulfide bridge. The background construct of the Y<sub>2</sub>R was depleted of solvent-accessible cysteines to avoid off-target labeling [38]. The final mutant construct (Y<sub>2</sub>R,Δ6Cys-A202<sup>45,49</sup>C) showed expression levels and G-protein activation similar to wild-type Y<sub>2</sub>R in HEK293 cells [39]. For CW-EPR analysis, Y<sub>2</sub>R was expressed in *E.coli*, purified, spin-labeled with iodoacetamide-proxyl (IAP) spin-label, and functionally reconstituted into phospholipid bicelles in vitro. We followed the Y<sub>2</sub>R folding process in vitro using a fluorescence-based assay employing the thiol-reactive fluorophore 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM). We confirmed the formation of the intramolecular disulfide bridge and successful spin labeling by alterations of CPM fluorescence (Figure 2A). Furthermore, we verified ligand binding for the spin-labeled receptor construct using established protocols (Figure 2B) [40,41].




**Figure 2.** Conformational dynamics of ECL2 in Y<sub>2</sub>R. (A) Confirmation of disulfide bridge formation and IAP spin labeling in the in vitro Y<sub>2</sub>R preparations by CPM-Assay. Since this thiol-reactive fluorescent probe is essentially non-fluorescent until it reacts with free thiols, high fluorescence intensity values identify free cysteines. The unfolded Y<sub>2</sub>R-A202<sup>45,49</sup>C,Δ6Cys construct contains three accessible cysteines, whereas the receptor folded into small bicelles has only one free Cys, as shown by the decrease in fluorescence intensity. The fluorescence intensity of the IAP-labeled variant (no free Cys) is similar to the control sample and confirms the proper thioether reaction. Reduction of the native disulfide bond by TCEP again liberates two sulfhydryl groups, while the thioether-formed bond between C202 and IAP is kept stable. (B) Ligand binding capacity of Y<sub>2</sub>R-A202<sup>45,49</sup>C,Δ6Cys (dark blue), and A202<sup>45,49</sup>-P1 (light blue) in vitro preparations, all containing the intact disulfide, was tested within a fluorescence polarization assay using K<sup>18</sup>-TAMRA-NPY. Based on the saturation curve, K<sub>d</sub>-values of 61.4 ± 2.9 nM for Y<sub>2</sub>R-A202<sup>45,49</sup>C,Δ6Cys, and 81.8 ± 5.1 nM for A202<sup>45,49</sup>-P1 were determined and are in the same nanomolar range as the K<sub>d</sub>-value of the wtY<sub>2</sub>RΔ6Cys with 63 ± 20 nM. (C) Room-temperature CW-EPR spectra of Y<sub>2</sub>R-A202<sup>45,49</sup>-P1 in the presence of varying amounts of reducing agent TCEP. All spectra represent a linear combination of three spectral components reflecting different dynamics (gray, bottom), which were determined by spectral fitting. (D) The titration of the reducing agent indicates a conformational equilibrium, which is modulated by the broken and intact disulfide bond, and which can be monitored by the population shift between components of fast and intermediate spin label dynamics, respectively. Data represent the normalized mean ± SEM of two independent experiments.

We chose the IAP spin label as it forms a non-reducible thioether bond to the spin label side chain P1. This enabled CW-EPR experiments in the presence of reducing agents to open the conserved extracellular disulfide. For analysis of the CW-EPR line shapes, we chose a simple isotropic motional model, which proved adequate for the simulation of all CW-EPR spectra acquired. We also tested more complicated models, including anisotropic motion, broadening, and ordering potentials; however, with no significant improvement of the spectral fits. The room-temperature CW-EPR spectrum of Y<sub>2</sub>R\_A202<sup>45,49</sup>-P1 (Figure 2C, no TCEP) is complex, caused by the superposition of at least two spectral components, each of which exhibit different spin label dynamics on the fast and intermediate nanosecond timescale. To gain a more quantitative picture of how the spin label dynamics and the underlying Y<sub>2</sub>R conformational states are modulated by the redox equilibrium of the disulfides, we performed a titration with the reducing agent tris(2-carboxyethyl)phosphine (TCEP). We detected a TCEP concentration-dependent change of the spectral line shape, namely an increase in intensity in the spectral regions characteristic of the most dynamic component (Figure 2C). CW-EPR line shape analysis suggests three components with different spin label dynamics, each characterized by a specific correlation time  $\tau_c$  (Figure 2C). The fast and intermediate components appear to share a TCEP-dependent equilibrium ( $c^{eq} = 0.37$  mM), and the immobilized component is constant across the entire TCEP titration (Figure 2D).

Accordingly, reduction of the ECL2-TM3 disulfide is associated with faster spin label dynamics (fast component) and hence, increased mobility of ECL2. On the other hand, as the population of intact disulfide is reduced, the EPR component with intermediate spin label dynamics is decreased, suggesting that the fast and intermediate populations are in equilibrium. Importantly, a significant amount of fast-moving spin labels is present even in the absence of a reducing agent (~5%), which indicates the presence of the broken disulfide even under non-reducing conditions. Notably, we also observe a slow-moving immobilized component in all spectra. As its population is not affected even in the presence of a 5 mM reducing agent, we suspect that the slow component reflects nonfunctional receptors or aggregates formed during the refolding procedure. Taken together, our CW-EPR analysis of ECL2 dynamics in Y<sub>2</sub>R supports the hypothesis that a missing disulfide leads to increased loop dynamics, which is related to compromised ligand binding, G protein activation, and arrestin recruitment in cellular assays (cf. Figure 1).


Following the finding of a highly flexible ECL2 in the absence of the disulfide constraint, we tested whether a re-fixation of the ECL2 to the TM3 via alternative disulfide bridges is sufficient to restore the signaling at the Y<sub>2</sub>R (Figure 3). For this, the cysteine at position C203<sup>45,50</sup> was retained while C123<sup>3,25</sup> was mutated to alanine, and the positions P120<sup>3,22</sup> and P127<sup>3,29</sup> were chosen as potential mutation sites as they were located on the same helix surface side as the native C3.25 but shifted by one helix winding up/downwards (P120<sup>3,22</sup>C/P127<sup>3,29</sup>C). To control for potential structural perturbations of mutating the proline residues in TM3 to cysteine, we introduced the P120<sup>3,22</sup>C and P129<sup>3,29</sup>C mutations in the presence of the native disulfide bridge (Figure 3C). While the P120<sup>3,22</sup>C variant showed nearly wild-type-like properties in the cAMP accumulation assay, the EC<sub>50</sub> of the P127<sup>3,29</sup>C variant was moderately shifted by nine-fold compared to the wild-type receptor (Figure 3C). Next, P120<sup>3,22</sup>C or P127<sup>3,29</sup>C, respectively, were introduced into the C123<sup>3,25</sup>A\_C203<sup>45,50</sup> background to enable the formation of alternative disulfides. Compared to the single cysteine C123<sup>3,25</sup>A\_C203<sup>45,50</sup> base variant, in both constructs with alternative disulfides G-protein signaling was further reduced and appeared completely abolished at a 10  $\mu$ M NPY concentration (Figure 3D,E). Given the very moderate effects of the single cysteine mutations P120<sup>3,22</sup>C or P127<sup>3,29</sup>C in the presence of the native disulfide, our findings suggest that the alternative disulfide bond has formed but fails to restore functionality and instead negatively affects activation.



**Figure 3.** Expression and biological activity of  $Y_2R$  cysteine shift variants. (A) Live cell fluorescence microscopy shows wild-type-like expression patterns of the disulfide-shifted variants. Pictures representative of two independent experiments, scale bar equals  $10\ \mu\text{m}$ . (B) Localization of the conserved cysteines C123<sup>3.25</sup> and C203<sup>45.50</sup> and the position of the alternative cysteines P120<sup>3.22</sup>C and P127<sup>3.29</sup>C. (C) Native  $G_{i/o}$  signaling was only mildly affected in the P120<sup>3.22</sup>C and P127<sup>3.29</sup>C control variants, thus allowing to test cysteine shift variants. (D) G-protein signaling was further reduced in the C123<sup>3.25</sup>A-P120<sup>3.22</sup>C and C123<sup>3.25</sup>A-P127<sup>3.29</sup>C cysteine shift variants. (E) Inositol monophosphate accumulation assays via a chimeric  $G_{qi}$  confirm the results of the cAMP assay and indicate an abolished G-protein signaling. Data represent the normalized means  $\pm$  SEM of  $n \geq 4$  (C),  $n \geq 3$  (D), and  $n \geq 2$  (E) independent experiments performed in technical triplicate.

These findings suggest that not only the presence but also the orientation of the conserved disulfide bridge are important for receptor function. We next chose to further limit the flexibility of the ECL2. For this, an additional constraint was introduced by connecting the ECL1 to the top of the  $\beta$ 2-strand of the ECL2 in the presence of the conserved disulfide bond. Based on the cryo-EM structure of  $Y_2R$  [24], we selected position E199<sup>45.46</sup> in ECL2 as it appeared to be in a suitable range and orientation to ECL1. In ECL1, the positions E115<sup>23.49</sup> and K117<sup>23.51</sup> were chosen (Figure 4B). As a control, we exchanged E199<sup>45.46</sup> for alanine and used this E199<sup>45.46</sup>A base variant to introduce E115<sup>23.49</sup>C and K117<sup>23.51</sup>C, respectively. In addition, the single cysteine variants E199<sup>45.46</sup>C, E115<sup>23.49</sup>C, and K117<sup>23.51</sup>C were created, and all constructs were tested in a cAMP accumulation assay (Figure 4C,D). While E199<sup>45.46</sup>A appeared wild-type-like, the introduction of a cysteine at this position resulted in a 98-fold shifted  $EC_{50}$  when compared to the wild-type. In both wild-type and E199<sup>45.46</sup>A background, K117<sup>23.51</sup>C displayed wild-type-like properties, underlining the suitability of this position to construct an additional disulfide bond. Similarly, the E115<sup>23.49</sup>C variants in the wild-type or E199<sup>45.46</sup>A background showed a seven to nine-fold shift in  $EC_{50}$ , making this position also amenable to constructing a disulfide to E199<sup>45.46</sup>C. We next created the corresponding double cysteine (“ECL connect”) variants E199<sup>45.46</sup>C-E115<sup>23.49</sup>C and E199<sup>45.46</sup>C-K117<sup>23.51</sup>C that allow the formation of the additional disulfide. For both ECL connect variants, a similarly strong loss of activity was detected in the  $G_{i/o}$

pathway (Figure 4E). The E199<sup>45.46</sup>C-K117<sup>23.51</sup>C variant showed a 3900-fold shifted EC<sub>50</sub>, and the E199<sup>45.46</sup>C-E115<sup>23.49</sup>C appeared even slightly further right-shifted and did not reach saturation at 1 μM NPY, which was likely caused by additional position-specific effects previously detected in the E115<sup>23.49</sup>C control variants (compare Figure 4D). Overall, the reduced activity of both double disulfide constructs by far exceeded the combination of the single cysteine controls, suggesting that the additional disulfide has formed and that the resulting increased rigidity impairs receptor activation.



**Figure 4.** Expression and biological activity of Y<sub>2</sub>R ECL connect variants. (A) Live cell fluorescence microscopy shows the expression pattern of a selection of the disulfide shift (control) variants. While E199<sup>45.46</sup>A-K117<sup>23.51</sup>C was wild-type-like, the C123<sup>3.25</sup>A-E199<sup>45.46</sup>A-K117<sup>23.51</sup>C variant showed a higher degree of intracellular trapping. Pictures representative of two independent experiments, scale bar equals 10 μm. (B) Localization of the selected residues to force an additional disulfide between the ECL1 and the ECL2. (C) In the native G<sub>i</sub> pathway, a severe loss of activity was detected for the E199<sup>45.46</sup>C-E115<sup>23.49</sup>C and E199<sup>45.46</sup>C-K117<sup>23.51</sup>C cysteine shift variants. When the E199<sup>45.46</sup>C-K117<sup>23.51</sup>C cysteine shift variant was combined with a C123<sup>3.25</sup>A mutation, the native G<sub>i</sub> signaling was further reduced. (D,E) Cysteine shift control variants were tested for their activity in the native G<sub>i</sub> pathway. E199<sup>45.46</sup>A appeared wild-type-like, while exchange to cysteine was less tolerated. K117<sup>23.51</sup>C and E199<sup>45.46</sup>A-K117<sup>23.51</sup>C were wild-type-like, while the G<sub>i</sub> signaling of E115<sup>23.49</sup>C and E199<sup>45.46</sup>A-E115<sup>23.49</sup>C was mildly impaired, which indicated that both positions were suitable to form an additional disulfide. Data represent the normalized means ± SEM of  $n \geq 2$  (C),  $n \geq 3$  (D), and  $n \geq 3$  (E) independent experiments performed in technical triplicate.

Nevertheless, we wondered whether the tethering of ECL1 to ECL2 could be helpful in a context where the native disulfide is absent. To probe this, we created a triple mutant in which the conserved disulfide bridge was disrupted via C123<sup>3.25</sup>A while ECL1 was connected to ECL2 via E199<sup>45.46</sup>C and K117<sup>23.51</sup>C. This construct was even less active than the E199<sup>45.46</sup>C-K117<sup>23.51</sup>C ECL connect double variant (Figure 4E) and the disulfide bridge-deficient C123<sup>3.25</sup>A single variant (Figure 1B), which may be attributed to a moderately impaired membrane expression (Figure 4A). This reinforced the idea that the sole fixation of ECL2 to keep the ligand binding pocket open is not sufficient to ensure correct receptor



function. Instead, a specific orientation and level of flexibility of ECL2 is required to enable specific conformations.


## 2.2. Receptor- and Pathway-Specific Role of the Conserved Disulfide in Different Peptide-Activated Rhodopsin-like GPCRs

After investigating the role of the conserved disulfide for the signaling of the  $Y_2R$ , we wondered whether the effects were universal to peptide-activated rhodopsin-like GPCRs. To test this, we turned to different receptors. First, we investigated possible differences within the neuropeptide Y receptor family and created disulfide bridge-deficient alanine variants for the  $Y_1R$ . Both  $Y_1R_{C113^{3.25}A}$  and  $Y_1R_{C198^{45.50}A}$  variants were expressed in the plasma membrane; however, a higher degree of intracellular trapping was observed when compared to the wild-type (Figure 5A). In the  $G_i$  pathway,  $C113^{3.25}A$  and  $C198^{45.50}A$  showed a similar signaling profile with a 20–26% loss of  $E_{max}$  and a 15–17-fold shift in  $EC_{50}$ , which was partially attributable to the reduced membrane expression of both variants (Figure 5B). In the inositol monophosphate accumulation assay using the chimeric G-protein, a 41% loss of  $E_{max}$  and 26-fold shifted  $EC_{50}$  was detected for  $C113^{3.25}A$ , while  $C198^{45.50}A$  appeared to be more strongly affected, showing a 57% loss of  $E_{max}$  and a 50-fold shift in  $EC_{50}$  (Figure 5C). This suggests position-specific effects for the  $C198^{45.50}A$   $Y_1R$  variant. Nevertheless, both assay systems indicated that the loss of the conserved disulfide bond only mildly affected the native  $G_i$  signaling, which contrasted with the observed severe impairment of the  $G_i$  signaling in the  $Y_2R$ .

Following this, we monitored the recruitment of arrestin3 to the  $Y_1R$  and the disulfide-deficient variants. Interestingly, no arrestin recruitment was detected in the disulfide deficient variants at 10  $\mu$ M NPY, even though the  $Y_1R$  is generally known to have a high affinity to arrestin3 [42] and showed half-maximal recruitment at 8 nM NPY. Accordingly, loss of the disulfide resulted in a >1220-fold loss in functional affinity for this pathway (Figure 5D).

Based on these findings, we concluded that loss of the conserved disulfide bridge leads to G-protein bias in the  $Y_1R$ . Since this may be explained by changes in the ligand binding pocket, we used the NanoBRET-based ligand binding assay to monitor affinity, but also (changes in) the binding orientation of the Tam-labeled NPY to the receptor variants. Interestingly, the netBRET signal of specific binding of the alanine variants was strongly reduced but at least saturable for  $C113^{3.25}A$  with a seven-fold shift in  $K_d$  compared to the wild-type  $Y_1R$ . The shift in binding affinity correlates well with the observed reduction of functional affinity in the G-protein pathway. The differences in the BRET window indicate a different binding orientation of the peptide at the  $C113^{3.25}A$  variant of  $Y_1R$ . Due to the very low signal window for the  $Y_1R_{C198^{45.50}A}$  construct, it remains unclear whether specific binding is precluded or occurs with very unfavorable BRET geometry that cannot be reliably detected, even though the functionality in the G-protein pathway rather argues for the latter scenario.


Together, these data suggest that the presence of the conserved disulfide bond is neither required for folding nor  $G_i$  signaling of  $Y_1R$ . In contrast, the disulfide was required for arrestin3 recruitment by  $Y_1R$ . This may arise from changes in the orientation of the peptide in the binding pocket upon removal of the conserved disulfide bond.



**Figure 5.** Expression and biological activity of  $Y_1R$  variants with a mutation in the conserved disulfide bridge. (A) Live cell fluorescence microscopy shows a mildly reduced membrane expression of the disulfide bridge deficient variants. Pictures representative of two independent experiments, scale bar equals 10  $\mu$ m. (B) Both  $Y_1R$  variants showed a similar signaling profile in the native  $G_{i/o}$  pathway, indicating a mild impairment of the G-protein signaling. (C) Inositol monophosphate accumulation assays via a chimeric G-protein confirmed the results of cAMP accumulation (D) C113<sup>3.25</sup>A and C198<sup>45.50</sup>A variants of the  $Y_1R$  did not recruit arrestin3 in BRET-based assays, thus indicating a severe impairment of the arrestin pathway. (E) In NanoBRET-based ligand binding assays, a severely reduced netBRET and a seven-fold shift in  $K_d$  were observed for  $K^{18}$ -TAMRA-NPY binding to  $Y_1R$ \_C113<sup>3.25</sup>A, while no specific peptide binding was detectable for the  $Y_1R$ \_C198<sup>45.50</sup>A variant. Data represent the normalized means  $\pm$  SEM of  $n \geq 5$  (B),  $n \geq 3$  (C), and  $n \geq 2$  (D,E) independent experiments performed in technical triplicate.

In addition to the receptors of the Y-receptor family, we chose to study two other peptide-activated receptors, the  $\mu$ -type opioid receptor (MOR) and the angiotensin II type 1 receptor (AT<sub>1</sub>R). Analogous to the workflow with NPY receptors, the conserved disulfide bond was removed via single alanine variants, and the expression of the receptor variants was first monitored by fluorescence microscopy. In contrast to the receptor variants of the Y receptor family, the membrane integration of the generated MOR variants MOR\_C142<sup>3.25</sup>A and MOR\_C219<sup>45.50</sup>A was severely impaired, which resulted in a high proportion of intracellularly located receptors (Figure 6A). We confirmed cell-surface expression by ELISA (Figure 6F) in agreement with a previous study [43], which allowed for functional characterization. As the MOR is known to be targeted by several endogenous peptides, we chose to use peptides of different lengths in combination with the receptor variants and used the short 4-mer endomorphin-1 and the longer 31-mer peptide  $\beta$ -endorphin. While wild-type MOR was activated by endomorphin-1 and  $\beta$ -endorphin with EC<sub>50</sub> values of 0.8 nM and 9.2 nM in the  $G_i$  pathway, respectively,  $G_i$  signaling was lost in both disulfide deficient variants when stimulated by either ligand (Figure 6B,C). Interestingly, an increase in cAMP levels was detected at high concentrations of endomorphin-1 and  $\beta$ -endorphin


in both wild-type MOR and its cysteine mutants. For wild-type MOR, such a  $G_i$ -to- $G_s$  switch has previously been proposed [44–46]. However, a similar response is also seen in untransfected cells and is, therefore, likely unspecific. We further wondered whether MOR variants were still able to recruit arrestin. For wild-type MOR, arrestin3 recruitment was measured for both ligands with  $EC_{50}$  of 375 nM for endomorphin-1 and >3000 nM for  $\beta$ -endorphin, respectively. Interestingly, despite wild-type stimulation with 10  $\mu$ M  $\beta$ -endorphin showing no saturation, a higher  $BRET_{total}$  was detected when compared to endomorphin-1, which suggested differences in the orientation of the receptor-arrestin complexes. In contrast, arrestin recruitment was not observed for the MOR\_C142<sup>3.25</sup>A and MOR\_C219<sup>45.50</sup>A variants (Figure 6D,E) using 10  $\mu$ M with either peptide ligand. Combined, the data indicate that the removal of the conserved disulfide bond severely impaired the signaling of the MOR.



**Figure 6.** Expression and biological activity of MOR variants with a mutation in the conserved disulfide bridge. **(A)** Live cell fluorescence microscopy in HEK293 cells shows a reduced yet detectable membrane integration of the disulfide bridge deficient variants. Pictures representative of two independent experiments, scale bar equals 10  $\mu$ m. **(B)** Cell surface ELISA verifies membrane expression of wild-type MOR and the disulfide-deficient variants. **(C,D)** cAMP reporter gene assays indicate a complete loss of the native  $G_i$  signaling in the C142<sup>3.25</sup>A and C219<sup>45.50</sup>A variants stimulated by the short endogenous agonist endomorphin-1 **(C)** or the long endogenous agonist  $\beta$ -endorphin **(D)**. An unspecific concentration-dependent increase in the cAMP level was detected for both variants and ligands. **(E,F)** Arrestin recruitment to the C142<sup>3.25</sup>A and C219<sup>45.50</sup>A variants was not detectable in BRET-based assays, irrespective of the ligand used. Data represent the normalized means  $\pm$  SEM of  $n = 3$  **(B)**,  $n \geq 4$  **(C)**,  $n \geq 4$  **(D)**,  $n \geq 2$  **(E)**, and  $n \geq 2$  **(F)** independent experiments performed in technical triplicate.

In contrast to the other selected receptors, the  $AT_1R$  was the only receptor in which the wild-type already showed only fractional membrane expression in transfected HEK293 and a high content of intracellularly located receptors (Figure 7A). A similar picture was also observed for the  $AT_1R$ \_C101<sup>3.25</sup>A and  $AT_1R$ \_C180<sup>45.50</sup>A variants; however, membrane integration was still detectable. We corroborated these findings with a cell surface ELISA (Figure 7D). In terms of  $G_q$  signaling,  $AT_1R$ \_C101<sup>3.25</sup>A, and  $AT_1R$ \_C180<sup>45.50</sup>A were hardly activated by the endogenous ligand angiotensin II (Figure 7B) compared to the wild-type that was activated with an  $EC_{50}$  of 1.2 nM. Severe loss of function was also detected in the

arrestin pathway. Arrestin3 was recruited by wild-type AT<sub>1</sub>R with an EC<sub>50</sub> of 3.6 nM but not to either disulfide bond deficient variant, indicating an >2770-fold impaired arrestin recruitment (Figure 7C). Taken together, the observations showed that the disruption of the conserved disulfide bridge receptor severely influenced receptor folding, arrestin recruitment, and G<sub>q</sub> signaling, leading to an essentially inactive receptor.




**Figure 7.** Expression and biological activity of AT<sub>1</sub>R variants with a mutation in the conserved disulfide bridge. **(A)** Live cell fluorescence microscopy in HEK293 cells showed a poor membrane expression of wild-type AT<sub>1</sub>R and disulfide bridge deficient variants. Pictures representative of two independent experiments, scale bar equals 10  $\mu$ m. **(B)** Cell surface ELISA confirms membrane expression of wild-type AT<sub>1</sub>R and disulfide-deficient variants. **(C)** Inositol monophosphate accumulation assays indicate a nearly complete loss of the native G<sub>q</sub> signaling. **(D)** Arrestin3 was not recruited to the C101<sup>3.25</sup>A and C180<sup>45.50</sup>A variants in BRET-based assays, thus indicating a severe impairment of the arrestin pathway. Data represent the normalized means  $\pm$  SEM of  $n \geq 2$  **(B)**,  $n \geq 2$  **(C)**, and  $n \geq 2$  **(D)** independent experiments performed in technical triplicate.

### 2.3. The Conserved Disulfide Bond Is Not Required for G-Protein Activation of Secretin-like GPCRs

Contrary to peptide-activated rhodopsin-like GPCRs, secretin-like GPCRs typically do not display a  $\beta$ -hairpin motif in the ECL2, which is accompanied by an overall shorter length of the ECL2 [31,47,48]. Nonetheless, the disulfide bridge between the ECL2 and TM3 is highly conserved in this subfamily as well [15], and the conserved cysteines are denoted as 3.29 and 45.50 in the Wootten numbering scheme [49]. To probe to which extent this disulfide is functionally required in secretin-like GPCRs similar to the rhodopsin-like peptide-activated subtypes, we selected two members of the secretin-like family; the corticotropin-releasing factor receptor 1 (CRF<sub>1</sub>R) and the glucagon-like peptide 1 receptor (GLP<sub>1</sub>R). Analogous to our approach for the rhodopsin-like GPCRs, two variants were created for each receptor in which the cysteines involved in the formation of the conserved disulfide bond were individually exchanged to alanine (Figure 8B). While the expression of the CRF<sub>1</sub>R\_C188<sup>3.29</sup>A and CRF<sub>1</sub>R\_C258<sup>45.50</sup>A variants appeared to be wild-type-like, both variants of the GLP<sub>1</sub>R showed reduced membrane integration with an increase in the amount of intracellularly located receptor (Figure 8A). We confirmed cell surface expression by cell surface ELISA (Figure 8F). cAMP accumulation assays were performed to monitor the signaling of the variants in their native G<sub>s</sub> pathway (Figure 8C,E). In the GLP<sub>1</sub>R

variants, the  $E_{max}$  remained unaffected, and the  $EC_{50}$  of the  $GLP_1R\_C296^{45.50}A$  variant was moderately right-shifted by 33-fold. The functional effects for  $GLP_1R\_C226^{3.29}A$  were stronger and showed a 322-fold shift in  $EC_{50}$ , in agreement with previously described position-specific effects of the free cysteine at position  $C226^{3.29}A$  in  $GLP_1R$  [50]. Similarly, for the  $CRF_1R$ , variant  $CRF_1R\_C188^{3.29}A$  was nearly wild-type-like with no changes in  $E_{max}$  and only a two-fold shift in the  $EC_{50}$ , while  $CRF_1R\_C258^{45.50}A$  was 10-fold right shifted when compared to the wild-type. Nonetheless, since the *minimal* functional change of either of the alanine mutants reflects the importance of the disulfide bridge, these effects were overall very mild for  $G_s$  activation of  $GLP_1R$  and  $CRF_1R$  despite the partially reduced membrane integration of the  $GLP_1R$  variants. We, therefore, concluded that the conserved disulfide bond is not required for the folding and G-protein signaling of these secretin-like GPCRs.



**Figure 8.** Expression and biological activity of  $CRF_1R$  and  $GLP_1R$  variants with a mutation in the conserved disulfide bridge. (A) Live cell fluorescence microscopy in HEK293 cells shows a wild-type-like expression of the  $CRF_1R$  variants, while the  $GLP_1R$  variants show a higher degree of intracellular trapping. Pictures representative of two independent experiments, scale bar equals 10  $\mu m$ . (B) Cell surface ELISA to verify membrane expression of the wild-type  $GLP_1R$  and the disulfide deficient variants. (C) Schematic representation of residues that are involved in the formation of the conserved disulfide. (D)  $GLP_1R$  variants were moderately less potent in the  $G_s$  pathway. (E) BRET-based arrestin recruitment assays reveal a severely reduced arrestin recruitment to the  $CRF_1R$  variants. (F) In the native  $G_s$  pathway,  $CRF_1R$  variants showed a wild-type-like ( $CRF188^{3.29}A$ ) or mildly impaired ( $CRF258^{45.50}A$ ) signaling. Data represent the normalized means  $\pm$  SEM of  $n = 7$  (B),  $n = 4$  (D),  $n \geq 2$  (E), and  $n = 4$  (F) independent experiments performed in technical triplicate.

While some form of G-protein signaling was also detectable in the disulfide bridge-deficient variants of the selected rhodopsin-like GPCRs, recruitment of arrestin3 was always lost under the given experimental conditions. We therefore tested whether the presence of the conserved disulfide bond was also a prerequisite for arrestin recruitment to peptide-activated secretin-like GPCRs. For this, we measured arrestin3 recruitment at the  $CRF_1R$  wild-type and the  $CRF_1R\_C188^{3.29}A$  and  $CRF_1R\_C258^{45.50}A$  variants by BRET. The wild-type  $CRF_1R$  recruited arrestin3 with an  $EC_{50}$  of 37 nM, while the  $CRF_1R\_C188^{3.29}A$  variant showed an eight-fold shift in  $EC_{50}$  as well as an 80% reduced  $BRET_{max}$  (Figure 8D). Arrestin recruitment to the  $CRF_1R\_C258^{45.50}A$  variant was even further blunted and did not reach saturation up to 10  $\mu M$  CRF. Together, the data suggest that the presence of the

conserved disulfide bond is required for the efficient recruitment of arrestin3 to secretin-like GPCRs, even in instances where G-protein activation is wild-type-like in the absence of the disulfide.

### 3. Discussion

The extracellular disulfide has generally been implicated in maintaining the integrity of the GPCR fold [21]. Additionally, it connects the  $\beta$ -hairpin folding motif conserved in the ECL2 of peptide-activated rhodopsin-like GPCRs to the TM3, which has mainly been considered to keep the binding pocket open [48]. Our data show that the conserved disulfide bond is not generally required for the structural integrity of peptide-activated GPCRs, as receptor variants lacking the disulfide are still membrane-expressed. In regards to signaling, the effects are very specific to each receptor and signaling pathway. G-protein activation is affected differently, but a common effect is seen for the recruitment of arrestin3, which is severely reduced and in most cases completely undetectable. CW-EPR experiments and the introduction of additional disulfides into the Y<sub>2</sub>R further indicate that a specific level of flexibility of the ECL2 is required for function.

We have initially used the human Y<sub>1</sub> and Y<sub>2</sub> receptors as prototypes to interrogate the functional contribution of the extracellular disulfide for the activation of G-proteins versus arrestin recruitment. Both receptor subtypes tolerated the loss of the disulfide very well for folding (compare Figures 1 and 5), enabling unambiguous functional interpretations. While the Y<sub>2</sub>R variants showed over 8000-fold reduced potency to activate G-proteins, G-protein activation of the corresponding Y<sub>1</sub>R variants was only moderately affected with ~20-fold shifted EC<sub>50</sub>. Interestingly, however, recruitment of arrestin3 to both mutated Y<sub>1</sub>R and Y<sub>2</sub>R was completely abrogated, equivalent to >1220-fold and >104-fold-reduced functional potencies. We note that there is hardly any receptor reserve in our G-protein activation assay setup [22]; therefore, the assays for G-protein activation and arrestin-recruitment have similar sensitivity. While at the Y<sub>2</sub>R, the potency to recruit arrestin3 was already very low at the wild-type receptor, precluding any conclusions on potential receptor bias, cysteine mutants of the Y<sub>1</sub>R were biased towards G-protein activation. Y<sub>1</sub> and Y<sub>2</sub> receptor subtypes are prototypic model systems for different modes of arrestin-recruitment, termed class A and class B arrestin-recruiting receptors [42,51–53]. Class A arrestin-recruiting receptors such as the Y<sub>1</sub>R co-internalize with arrestin bound and have a tight interaction of their phosphorylated C-termini with arrestin, enabling stable interactions in a ‘tail’-configuration that does not require contacts of the TM domain with arrestin finger- or middle loops [42,51]. Class B type arrestin-recruiting receptors such as the Y<sub>2</sub>R display arrestin interactions only at the plasma membrane, and the protein complex involves contacts of the receptor TM core and phosphorylated C-terminal tail [42,51]. Both interaction types seem to be strongly destabilized by mutation of the disulfide bridge, possibly already at the level of receptor phosphorylation by GRKs or ligand residence time. Arrestin recruitment to GPCRs is a slow multistep process. We suggest that the disulfide increases ligand residence time, which is essential for efficient GPCR phosphorylation and arrestin binding. Interestingly, a reduction in ligand residence time in LSD-stimulated 5-HT<sub>2A</sub>R and 5-HT<sub>2B</sub>R variants bearing a mutation in the ECL2 was previously shown to reduce the potency of  $\beta$ -arrestin-2 recruitment but not of the G<sub>q</sub>-mediated signaling, which supports this hypothesis [54]. Similarly, cysteine mutants of AT<sub>1</sub>R and MOR also showed no detectable interaction with arrestin, and even the secretin-family CRF<sub>1</sub>R that has very mild effects on G-protein activation has drastically reduced arrestin recruitment (see below).

G-protein activation of the diverse GPCRs tested was affected much differently. The effects were not correlated with different types of G-protein, as G<sub>i</sub> activation was moderately (Y<sub>1</sub>R), very strongly (Y<sub>2</sub>R), or completely (MOR) abrogated, respectively. G<sub>q</sub> coupling of the AT<sub>1</sub>R mutants was completely absent. Therefore, the specific effects are likely related to the individual architecture of the respective binding pockets.


The AT<sub>1</sub>R was essentially inactive upon loss of the conserved disulfide. In this receptor, the conserved  $\beta$ -hairpin structure is extended by another  $\beta$ -strand, which is contributed by the distal N-terminus. Interestingly, a second extracellular disulfide links the membrane-proximal part of the NT with ECL3. This structure limits the accessibility of and leads to a narrower binding pocket [27,28]. It is likely that the loss of the structural constraint increases the flexibility of the  $\beta$ 2-strand, allowing it to move into the binding pocket and, thus, occlude ligand binding to the AT<sub>1</sub>R.

Next, we selected the  $\mu$ -type opioid receptor (MOR), which is activated by a variety of structurally diverse ligands [25,26]. No specific activation was detectable in the disulfide-deficient variants stimulated by the endogenous peptide  $\beta$ -endorphin (31mer) bearing the common C-terminal YGGF opioid motif as well as the short peptide endomorphin-1 (4mer) consisting of the modified YPWF motif. While the two ligands appear heterologous, structural data reveal that both stabilize similar active structures [26]. The ligand binding pocket of the MOR appears to be quite large. In contrast to the short peptide endomorphin-1, whose interactions are limited to the deeper binding pocket, it was shown that  $\beta$ -endorphin additionally interacts with the ECL2, which in the MOR was proposed to function as a selectivity filter for different opioid peptides, and the extracellular ends of TM1 and TM2 [26]. These additional contacts to the ECL2 are not sufficient to rescue the canonical G-protein signaling. Instead, loss of the extracellular disulfide seems to loosen the hydrophobic binding pocket between ECL1 and TM3 that accommodates the opioid “message” sequence YGGF/YPWF or may affect ligand residence time.

While the MOR was used as a prototype for a receptor activated by structurally different peptides, we also looked into the Y<sub>1</sub>R and Y<sub>2</sub>R, which are both activated by the same endogenous ligand NPY and hence have more similar steric requirements in the binding pocket. G-protein signaling was markedly less affected in Y<sub>1</sub>R than in Y<sub>2</sub>R. We speculate that additional interactions stabilize NPY binding to the Y<sub>1</sub>R in the absence of the conserved disulfide and ameliorate the effects. Indeed, several differences in the ligand binding mode of NPY to the Y receptors can be found [22–24]. Most notably, the Y<sub>1</sub>R possesses an additional binding pocket for the N-terminus of NPY, which contributes to ligand binding and signaling [24]. In the active Y<sub>1</sub>R, the positions of the extracellular ends of the TM helices and EC loops are more similar to the inactive state. In the NPY-bound Y<sub>2</sub>R structure, the extracellular ends of TM2 and TM6 contract towards the agonist in a pincer-like movement compared to the inactive snapshot [23]. The ECL2 strongly engages in interactions with a hydrophobic patch in the NPY helix, which is crucial for receptor binding and the correct orientation of the C-terminal residues involved in receptor activation [24]. It appears reasonable that the increased flexibility of the ECL2 induced by the removal of the conserved disulfide would destabilize essential contacts to the peptide and hence the contraction of the extracellular parts of the receptor. While this effect would certainly take place in both receptors, the overall reduced number of interactions in the Y<sub>2</sub>R renders the receptor more prone to changes in the main interaction patch.

The ECL2 of Y<sub>1</sub>R and Y<sub>2</sub>R are amongst the most mobile components of the receptor, as judged by the low local resolutions in the cryo-EM structures [24]. We turned to CW-EPR with purified receptors that carry a site-specific label in ECL2 to investigate changes in loop flexibility in more detail. Surprisingly, the EPR signal contained signatures of fast and intermediate mobility already in the basal state, suggesting that there is an equilibrium of an oxidized and reduced disulfide state that might both contribute to the specific inherent functional profile of Y<sub>2</sub>R. This chemical reduction by adding TCEP increased the fast mobility component, providing a molecular basis for the interpretation of our functional data. Reduction of the conserved disulfide bridge did not lead to a collapse of the binding pocket but rather indicated an increase in ECL2 flexibility. This data is in accordance with early FTIR spectroscopic results on rhodopsin activation that suggested a transient cleavage of the extracellular disulfide occurring in one of the activation intermediates [55] and implies that in this more flexible ECL2 conformation peptide-receptor contacts are weakened.

Structural snapshots obtained via cryo-EM showed that the ECL2 may be flexible enough to interact with ECL1 [24]. Thus, we introduced additional cysteines into the ECL2 and ECL1 to introduce an additional disulfide. The accompanying reduction in flexibility severely impaired receptor function (compare Figure 4). Moreover, shifting the connection to TM3 by one helix winding from C3.25 to 3.22 or 3.29 rendered the receptor completely inactive. Thus, our results indicate that the conformational dynamics of ECL2 are tightly regulated by the exact positioning of the disulfide, which is essential for the activity of Y<sub>2</sub>R (Figure 9).



**Figure 9.** Fine-tuned flexibility of the ECL2 is important for the function of the Y<sub>2</sub>R. In the wild-type receptor (**middle**), which is fully capable of recruiting arrestin3 and activating the G<sub>i</sub> pathway, the ECL2 is constrained via the conserved disulfide bond and displays moderate flexibility. When the conserved disulfide is lost (**right**), the flexibility of the ECL2 is increased. G-protein signaling is severely impaired yet still detectable, while arrestin recruitment is completely abolished. In the opposite scenario (**left**), the ECL2 flexibility is reduced by introducing additional disulfide bridges or a shift in the positioning of the conserved disulfide bond. In this case, arrestin recruitment and G-protein signaling are nearly completely lost.

Contrasting to the specific but often severe functional impairments of rhodopsin-like receptors resulting from removing the conserved disulfide, the effects on G-protein signaling remain mild for the tested secretin-like GPCRs CRF<sub>1</sub>R and GLP<sub>1</sub>R. Surprisingly, arrestin recruitment was still severely impaired, with an 80% reduced BRET window in the CRF<sub>1</sub>R variants. Based on this finding, we speculate that specific structural features of secretin-like GPCRs stabilize ligand binding and G-protein activation but are not sufficient to trigger arrestin interactions. In contrast to rhodopsin-like receptors, in secretin-like GPCRs, a larger and well-ordered NT domain strongly stabilizes peptide binding [3,56]. This seems to be a specific adaptation to peptide ligands [3,56], while the rhodopsin family displays a variety of ligand classes with varying sizes. In turn, the ECL2 of secretin-like receptors is shorter and lacks the  $\beta$ -hairpin folding motif [57]. While rhodopsin-like and secretin-like GPCRs form separate phylogenetic clusters [3], it is hypothesized that both classes derive from a common ancestral peptide receptor that already contains the  $\beta$ -hairpin motif [58]. This raises the question of whether the original function of the specifically folded ECL2 was at least partially transferred to the newly occurring N-terminal domain, thus lowering the evolutionary pressure to retain previously conserved structural elements. Nonetheless, the ECL2 of secretin-like receptors is still involved in



peptide binding [50,59–63], and the TM3-ECL2 linking disulfide bond remains highly conserved [15]. While not essential for G-protein activation, the ECL2 might also be involved in fine-tuning ligand residence time. In the current model, ligand binding to secretin-like GPCRs is composed of a two-step-based mechanism [62,64–67]. First, the C-terminal fragment of the ligand binds to the N-terminal domain of the receptor which triggers structural rearrangements inside the ligand. Next, the N-terminal fragment binds to the orthosteric binding pocket of the receptor, which leads to receptor activation. In this scenario, we hypothesize that the disruption of the conserved disulfide still allows for the normal binding procedure. In the fully bound state, however, the increased flexibility of the ECL2 destabilizes interactions of the TM domain to the N-terminal part of the ligand, which may reduce ligand residence time. The ligand might then revert to a half-bound state in which its C-terminal ligand fragment remains bound to the N-terminal extracellular domain of the receptor while the peptide's N terminus partly dissociates from its 'final' binding position, which destabilizes the active conformation. In contrast to rhodopsin-like receptors in which an immediate full dissociation of the ligand-receptor-complex is expected after the loss of the conserved disulfide, the two-step mechanism of secretin-like GPCR would allow for a fast re-association of the active complex, explaining the milder effect on G-protein coupling, while recruitment of arrestin requires a long-lived, fully engaged complex.

#### 4. Conclusions

The present study demonstrates that the function of the conserved disulfide bond in peptide-activated GPCRs exceeds an involvement in GPCR folding. Its removal in peptide-activated receptors leads to a receptor-specific impairment of G-protein signaling, while arrestin recruitment is completely abolished. Experiments with the Y<sub>2</sub>R further show that the disulfide bond maintains a specific level of flexibility of the ECL2. We found an equilibrium of oxidized and reduced disulfide bonds for Y<sub>2</sub>R, with the cleaved disulfide conformation exhibiting increased ECL2 dynamics. We hypothesize that the disulfide bridge is important to increase ligand residence time. The cleavage of the disulfide leads to a shift of the conformational equilibrium manifesting in altered ligand- and transducer binding properties, which eventually leads to impairment of G-protein signaling and quantitative depletion of arrestin recruitment.

#### 5. Methods

##### 5.1. Generation of Plasmids

We used a genetic fusion of the receptors and variants of the enhanced green fluorescent protein (eGFP, eYFP) for transient transfection in all assay systems. For cAMP reporter gene assays, inositol monophosphate accumulation assays, BRET-based arrestin recruitment assays, fluorescence microscopy, and cell surface ELISA HA-Y<sub>2</sub>R-eYFP\_N1, Y<sub>1</sub>R-eYFP\_N1, AT<sub>1</sub>R-eYFP\_N1, MOR-eYFP\_pVitro2, GLP<sub>1</sub>R-eGFP\_pcDNA3.1 constructs were used, which all carried the canonical receptor isoform. For the FLAG-CRF<sub>1</sub>R-eGFP\_N1 receptor, the R2 isoform (P34998-2) was used. For nanoBRET-based binding assays, we devised the previously described N-terminally nanoluciferase-fused Nluc-Y<sub>2</sub>R-eYFP\_N1 and Nluc-Y<sub>1</sub>R-eYFP\_N1 constructs [24]. Receptor variants bearing the required point mutations were generated by site-directed mutagenesis using partially overlapping primers as described [68]. The plasmids were amplified in *E. coli* DH5 $\alpha$ , purified using the ZymoPure II Kit (Zymo Research, Irvine, CA, USA), and all sequences were verified by Sanger sequencing.

##### 5.2. Peptide Synthesis

Peptide synthesis was performed using the fluorenylmethoxycarbonyl (Fmoc)/*tert*-Butyl (*t*Bu) strategy in 15  $\mu$ mol scale in a Syro II robot (Multisynthetech, Witten, Germany) as described previously [69]. Briefly, for the generation of C-terminally amidated peptides, Rink amide or TGRam resins were used. For peptides containing C-terminal free acids, pre-loaded Wang resins were elongated. The peptide sequence was built using

repeated cycles of Fmoc-deprotection with 40%/20% piperidine in DMF for 3 min and 10 min and double coupling of 8 eq. Fmoc-amino acid with 8 eq. Oxyma (ethyl 2-cyano-2-(hydroxyimino)acetate) for 45 min each. The 5/6-tetramethylrhodamine (TAMRA) fluorophore was coupled manually via the free acid at an orthogonally protected Lys(Dde) using 2 eq. TAMRA, 1.9 eq. HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate, hexafluorophosphate azabenzotriazole tetramethyl uronium) and 2 eq. diisopropylethylamine in DMF overnight as described [23]. Resins and protected amino acids were purchased from Iris Biotech (Marktredwitz, Germany). Peptide purification and analytics were performed by preparative/analytical RP-HPLC (Shimadzu/VWR) using gradients of acetonitrile in water at pH 2 as eluents on Aeris Peptide 5u XB-C18, Jupiter 4u Proteo 90 Å (C12), or Aeris Peptide 3,6 n XB-C18 columns (Phenomenex, Torrance, CA, USA). The purity of all peptides was > 95%. In addition, MALDI (Bruker, Billerica, MA, USA) Ultraflex III MALDI TOF/TOF and ESI-Orbitrap-based mass spectrometry (Bruker, Billerica, MA, USA) was used to confirm peptide identities.

### 5.3. Cell Culture

All cell-based experiments were performed in HEK293 cells (human embryonic kidney, DSMZ, Braunschweig, Germany). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) and HAM's F12 (1:1, *v/v*, Lonza, Basel, Switzerland) supplemented with 15% (*v/v*) heat-inactivated fetal bovine serum (FBS, Lonza, Basel, Switzerland) in T75 cell culture flasks at 95% H<sub>2</sub>O, 37 °C, and 5% CO<sub>2</sub>.

### 5.4. Fluorescence Microscopy

The localization of all generated receptor variants was monitored by live-cell fluorescence microscopy. 150,000 HEK293 cells in a total volume of 300 µL were seeded into 8-well µ-slides (Ibidi, Gräfelfing, Germany) and cultured to a confluence of 70%. The cells were then transfected with 500 ng of the respective receptor construct using Lipofectamine2000 (Invitrogen, Waltham, MA, USA) according to the manufacturer's protocol. On the following day, the medium was removed and replaced with Opti-MEM (Thermo Fisher Scientific, Waltham, MA, USA) containing 2.5 µg/mL Hoechst 33342 nuclear stain (Thermo Fisher Scientific, Waltham, MA, USA). After incubation for 10 min, the cells were subsequently monitored using an Axio Observer Z1 microscopic setup with ApoTome.2 (Zeiss, Oberkochen, Germany: 63×/1.4 oil objective, filter settings (ex/em): YFP 500 nm (20)/535 nm (30), DAPI 365 nm (20)/420 nm (30)). Identical acquisition times and image processing were applied for wild-type and receptor mutants.

### 5.5. cAMP Reporter Gene Assay

The activation of the G<sub>s</sub> and G<sub>i/o</sub> pathways was monitored by cAMP reporter gene assays. HEK293 cells were seeded into 6-well plates. At a confluence of 70%, the cells were co-transfected (MetafectenePro, Biontex, München, Germany) with 2 µg of the respective receptor construct and 2 µg of the pGL4.29 [CRE/Luc2P/Hygro] reporter gene (Promega, Madison, WI, USA, total 4 µg DNA in 1:1 ratio) according to the manufacturer's protocol. The transfected cells were re-seeded into 384 well plates at a density of 15000 cells/well. After 24 h, the medium was replaced by 15 µL of a stimulation solution consisting of the respective peptides in unsupplemented DMEM, adding 2 µM Forskolin for G<sub>i</sub>-coupled receptors (Y<sub>1</sub>R, Y<sub>2</sub>R, MOR). As a negative control, cells were treated with DMEM, while for the positive control, cells were stimulated with DMEM containing 2 µM/10 µM Forskolin (G<sub>i</sub>/G<sub>s</sub>). All simulations were performed in technical triplicate. After 3 h of incubation, the cells were lysed with 15 µL of OneGlo solution (Promega, Madison, WI, USA). Luminescence values were measured after 5 min in a Spark plate reader (Tecan, Männedorf, Switzerland, *t*<sub>integration</sub> = 500 ms). Data were normalized to the minimal (negative control) and maximal luminescence. The means of the independent experiments were pooled and fit to a three-parameter-based agonist (log) vs. response non-linear regression (GraphPad Prism 5, San Diego, CA, USA).

### 5.6. Inositol Phosphate Accumulation Assay

The activation of the G<sub>q</sub> pathway was monitored by a commercial homogenous time-resolved fluorescence (HTRF)-based inositol phosphate (IP<sub>1</sub>) accumulation assay in transiently transfected HEK293 cells as described recently [70]. Briefly, HEK293 were co-transfected with 3.2 µg of the respective receptor construct and either 0.8 µg of an empty pcDNA3.1 vector (natively G<sub>q</sub>-coupled receptors) or 0.8 µg of a Giq4Δmyr-chimera (G<sub>i</sub>-coupled receptors) [34] using MetafectenePro (Biontix, München, Germany) according to the manufacturer's protocol, and subsequently seeded into 384-well plates at a density of 20000 cells/well. On the next day, the medium was removed and replaced by 15 µL of a stimulation solution containing the respective peptide dilution in Hank's balanced salt solution (HBSS) and 20 mM LiCl. For the detection of the inositol monophosphate, specifically labeled antibodies of the IP-One Gq kit (Cisbio, PerkinElmer, Waltham, MA, USA) were used according to the manufacturer's protocol. The HTRF signal was read out using a Spark plate reader (Tecan, Männedorf, Switzerland, filter settings (ex/em): 320/620 nm (donor)–320/665nm (acceptor)). The measured values were normalized to the wild-type control (minimum/maximum response). The normalized means of the independent experiments were pooled and fit to a three-parameter-based agonist (log) vs. response non-linear regression (GraphPad Prism 5, San Diego, CA, USA).

### 5.7. Arrestin Recruitment Assay

Arrestin recruitment to the receptor variants was monitored by a BRET-based approach. HEK293 cells were seeded into 6-well plates. At a confluence of 70%, the cells were co-transfected (MetafectenePro, Biontix, München, Germany) according to the manufacturer's protocol. A total of 4000 ng DNA was transfected per well. In the first set of experiments, we performed receptor titration experiments to determine the receptor-to-arrestin-ratio that ensures saturation of the luminescence donor (Nluc-arr3) by the fluorescence acceptor (receptor-eYFP) and hence, results in reproducible measurement window for ligand concentration-response curves. Accordingly, we chose to transfect 30 ng of a modified Nluc-tagged bovine arr-3 construct [71], 3900 ng receptor construct, and 70 ng of an empty pcDNA3.1 vector. After the transfection, 150,000 cells/well were re-seeded into solid white 96-well plates in technical triplicate using a phenol red-free culture medium. For the assay, the medium was replaced by a 100 µL of BRET buffer (HBSS + 20 mM HEPES, pH 7.4 50 µL of a coelenterazine H solution (Nanolight, Prolume, Pinetop, AZ, USA) 16.8 µM in BRET buffer) were added, and the plate was incubated for 5 min at 37 °C. 50 µL of the agonistic peptide solution were added (varying peptide concentrations between 0.01 nM to 10 µM; final volume in all conditions 200 µL). Fluorescence and luminescence values were measured well-wise at three time points (5, 10, and 15 min post-stimulation) using a Spark plate reader (Tecan, Männedorf, Switzerland, filter settings: 400–470 nm (luminescence); 535–650nm (fluorescence)). Raw BRET values were calculated well-wise by dividing the fluorescence values by the detected luminescence values. netBRET values were then calculated by subtracting the BRET values of the buffer control. The corrected values were either normalized to the respective wild-type receptor or the means were directly pooled and fit a three-parameter-based agonist (log) vs. response non-linear regression (GraphPad Prism 5, San Diego, CA, USA).

### 5.8. NanoBRET Ligand Binding Assay

BRET-based ligand binding assays were performed using membrane preparations of transiently transfected HEK293 cells expressing Nluc-Y<sub>1/2</sub>R-eYFP receptors as described recently [24]. Briefly, 0.03 µg total protein per well was suspended in ice-cold HBSS containing 20 mM HEPES (pH 7.4), Pefabloc, and 0.1% bovine serum albumin (BSA), corresponding to a total luminescence of 500.000–1.000.000 RLU. The assay was performed in solid black 96 WP with a total assay volume of 100 µL. The TAMRA-labeled peptides were prepared as 10× stock in HBSS containing 20 mM HBSS/HEPES (pH 7.4) and 0.1% BSA, added to the membranes and incubated for 10 min at room temperature with gentle

agitation (total binding). To determine unspecific binding, 100-fold excess of unlabeled NPY or specific receptor antagonist BIBP3226 (Y<sub>1</sub>R; [72]) or JNJ-31020028 (Y<sub>2</sub>R; [73]) was added.

10 µL of coelenterazine H (42 µM) in HBSS/HEPES (pH 7.4) were added to each well, and BRET was measured using a Spark plate reader (Tecan, Männedorf, Switzerland, well-wise mode, filter settings: 430–470 nm (luminescence); 550–700 nm (fluorescence)). Raw BRET values were calculated well-wise by dividing the fluorescence values by the detected luminescence values. NetBRET values were calculated by subtracting the BRET values of buffer controls. Specific binding was determined by correcting the total binding for unspecific binding. The corrected values were fit in a biphasic non-linear regression and plotted as a function of the concentration of the labeled peptide (GraphPad Prism 5, San Diego, CA, USA).

### 5.9. Cell Surface ELISA

Membrane expression of selected receptor variants was confirmed by cell surface ELISA. HEK293 were seeded in 6 WP and transiently transfected with 3 µg DNA using MetafectenePro (Biontex, München, Germany) according to the manufacturer's protocol. The cells were re-seeded into poly-D-lysine-coated transparent 96-well plates at a density of 150,000 cells/well and cultivated overnight in complete medium, followed by 30 min serum-deprivation using Opti-MEM (Thermo Fisher Scientific, Waltham, MA, USA). The cells were subsequently fixated with 50 µL PFA (2% in phosphate-buffered saline (PBS)) on ice for 60 min and washed three times with 150 µL PBS. Next, unspecific binding was blocked with full medium (surface receptors) or full medium + 0.5% Triton-X 100 (permeabilization to determine total receptors) for 60 min at room temperature. The cells were rinsed once with 150 µL PBS per well. Primary antibodies were diluted in DMEM + HAM's F12 (1:1, v/v, + 7.5% FBS v/v) as follows: anti-AT<sub>1</sub>R (ab124734, rabbit, Abcam, Cambridge, UK) 1:1000, anti-MOR (SAB4502048, rabbit, Sigma-Aldrich, St. Louis, MO, USA) 1:1000, anti-GLP<sub>1</sub>R (sc-390774, mouse, Santa Cruz Biotechnology, Dallas, TX, USA) 1:60. Dilutions of the respective primary antibodies were incubated for 120 min at room temperature. A negative/specificity control was included for every receptor and incubated with DMEM + HAM's F12 (1:1, v/v, + 7.5% FBS v/v) without a primary antibody. The cells were then washed three times with 150 µL PBS per well. Horseradish peroxidase (HRP) coupled Anti-Rabbit IgG H&L (AT<sub>1</sub>R, MOR, ab205718, goat, Abcam, Cambridge, UK, 1:10000) and m-IgGκ BP (GLP<sub>1</sub>R, sc-516102, Santa Cruz Biotechnology, Dallas, TX, USA, 1:1000) antibodies were diluted in DMEM + HAM's F12 (1:1, v/v, + 7.5% FBS v/v) and incubated for 120 min at room temperature. The cells were washed four times with 150 µL PBS per well and subsequently incubated with 100 µL of 3,3',5,5'-tetramethylbenzidine (TMB) for 3 min. The reaction was stopped with 100 µL of 0.25 M HCl to obtain a stable yellow color, and the absorption at 450 nm was measured in an Infinite M200 Plate reader (Tecan, Männedorf, Switzerland). Absorption values were corrected by subtracting the mean of the negative controls of the respective receptor. The resulting values of the non-permeated samples (membrane expression) were divided by the values of the permeated samples (total expression). The assays were conducted 2–7 times independently in technical triplicate. The means of the corrected values from the individual assays were pooled and displayed as fractions of the respective total expression.

### 5.10. In Vitro Sample Preparation of Y<sub>2</sub>R-A202<sup>45.49</sup>C, Δ6Cys in Small DMPC/DHPC Bicelles for CW-EPR

Sample preparation of the cysteine deficient Y<sub>2</sub>R\_A202<sup>45.49</sup>C,Δ6Cys variant in small 1,2-dimyristol-sn-glycerol-3-phosphocholine (DMPC)/1,2-diheptanoyl-sn-glycero-3-phosphocholine (DHPC) bicelles was performed as described previously [39,74]. Briefly, the cDNA of Y<sub>2</sub>R\_A202<sup>45.49</sup>C-Δ6Cys-polyHis was introduced into a pET41b vector system, and proteins were expressed as inclusion bodies during a fed-batch fermentation in *Escherichia coli* NiCo21 cells, followed by solubilization in a sodium phosphate buffer supplemented with 15 mM SDS and 50 mM DTT. The receptor was purified by metal affinity chromatog-

raphy (NiNTA). Before in vitro folding and nitroxide spin labeling, the sample was diluted to 0.5 mg/mL and treated with 5 mM TCEP to fully reduce the three remaining cysteines of the receptor and thus prevent unspecific disulfide bridges or oligomer formation. TCEP was then removed by several dialysis steps against 25 mM degassed TRIS/HCl containing 15 mM SDS (pH 7). Next, the SDS concentration was decreased to 1 mM while introducing a redox-shuffling system (1 mM GSH and 0.5 mM GSSG) to facilitate the formation of the conserved disulfide bond. Subsequently, the receptor was reconstituted into small DMPC/DHPC bicelles ( $q < 0.25$ ) using a molar ratio of 1: 600: 2400 of receptor: DMPC: DHPC. Spin-labeling of the single remaining free cysteine at position A202<sup>45,49</sup>C in the extracellular loop 2 with 3-(2-iodoacetamido)-proxyl (IAP) was achieved by adding three-times 10-fold molar excess to the receptor sample (incubation  $2 \times 2$  h at room temperature and  $1 \times$  overnight at 4 °C). To fully remove unbound spin-label from the sample, the receptor was (partially) unfolded and refolded a time using the above protocol excluding the reducing agent and redox-shuffling system. Spin concentration produced the final sample used for the EPR experiments containing  $\sim 30$   $\mu$ M P1 labeled receptor in 25 mM TRIS/HCl buffer, pH 7.

#### 5.11. CPM Assay

Disulfide bridge formation and spin labeling were evaluated in a fluorescence-based assay system using a thiol-reactive fluorochrome N-[4(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM) as described previously [39]. A 4 mg/mL CPM stock solution was prepared in DMSO and further diluted 40-fold in 25 mM Tris/HCl buffer pH 7 to a concentration of 0.1 mg/mL. Simultaneously, a total amount of 5  $\mu$ g receptor protein from each sample was re-suspended in 15 mM SDS containing 25 mM Tris/HCl buffer, pH 7, to a final volume of 360  $\mu$ L. The receptor samples were then mixed with 30  $\mu$ L of the prepared CPM solution and incubated in the dark for 30 min at room temperature. Fluorescence intensities were determined on a Spark Reader (Tecan, Männedorf, Switzerland) using an excitation wavelength of 387 nm, scanning emission wavelength from 450 to 500 nm, and an integration time of 0.5 s. All samples were scanned three times at 20 °C.

#### 5.12. Fluorescence Polarization Assay

To determine the ligand binding capacity of the Y<sub>2</sub>R\_A202<sup>45,49</sup>C in small bicelles and the IAP-labeled variant, we performed a fluorescence polarization assay as described previously [74]. Therefore, various concentrations of the receptor constructs were incubated with 50 nM (K<sup>18</sup>-TAMRA)-NPY for 1 h at room temperature and transferred as triplicates in a 96-well plate (Corning, non-binding surface, # CLS3881, Corning, NY, USA). Fluorescence polarization was measured using the Spark Microplate Reader (Tecan, Männedorf, Switzerland) with linearly polarized light, an excitation wavelength of 549 nm, an emission wavelength range of 574 to 578 nm, and a 90° detection angle at 20 °C. A sigmoidal dose-response curve was used to fit the data with the 'OriginPro,2019' software.

#### 5.13. Continuous-Wave (CW)-EPR Measurements

The following sample set was prepared for CW-EPR measurements: (1) a control sample of free IAP (100  $\mu$ M) with empty bicelles in Tris/HCl buffer pH 7 and (2) Y<sub>2</sub>R\_A202<sup>45,49</sup>C, 6Cys-IAP (A202<sup>45,49</sup>-P1,  $c = 40$   $\mu$ M) in small bicelles. Next, titration experiments with increasing concentrations of the reduction reagent TCEP were performed. A 50 mM TCEP stock solution in 25 mM TRIS/HCl buffer (pH 7) was prepared, and aliquots of A202<sup>45,49</sup>-P1 were then treated for 45 min at room temperature with TCEP in a range of 0.001 mM to 5 mM. All samples were added to '50  $\mu$ L-Blaubrand' borosilicate capillaries (I.D. 0.85 mm, O.D. 1 mm, ref.-number: 708733, Brand GmbH, Wertheim, 97877 Germany, Germany).

X-Band ( $\sim 9.6$  GHz) room temperature CW-EPR spectra were obtained on a Bruker EMXmicro spectrometer (Bruker, Karlsruhe, Germany). Measurements were performed using the high-sensitivity dielectric resonator (ER4123D) at 20 db attenuation (2 mW), 100 kHz modulation frequency, and modulation amplitude of 0.3 mT. The final spectra

represent an average of 150 scans, using a scan width of 12 mT at a sampling rate of 0.8 mT/s.

EPR spectra were simulated using the software package MultiComponent v.1034 (developed by the laboratory of Wayne Hubbell at UCLA, available under <https://www.biochemistry.ucla.edu/Faculty/Hubbell/software.html>) (accessed on 9 January 2023). The default values for magnetic ( $g$ ) and hyperfine ( $A$ ) tensors were used ( $g_{xx} = 2.0078$ ,  $g_{yy} = 2.0058$ ,  $g_{zz} = 2.0023$ ,  $A_{xx} = 5.7$  G and  $A_{yy} = 6$  G) and first validated in the simulation of free IAP (P1) in the empty bicelles spectrum. The isotropic simulation yielded the rotational correlation time of  $\tau_c = 45$  ps and the hyperfine splitting tensor  $A_{zz}$  of 36.12 G. In the next step, we simulated the spectra of  $Y_2R-A202C^{45,49}$ -P1 treated with 5 mM TCEP applying a three-component system with variable  $R1$ ,  $A_{zz}$ , phase, and  $B_0$ , plus amplitudes (scales). The most relevant fitting parameters are for the fast component  $A_{zz} = 36.1$  G,  $t_c = 0.282$  ns; for the intermediate component  $A_{zz} = 37.71$  G,  $t_c = 2.62$  ns and for the immobilized component  $A_{zz} = 34.76$  G,  $t_c = 10.7$  ns. Including ordering potentials, motional anisotropy, or line broadening in either of the components led to only negligible improvements in the fit. To fit the spectra recorded at variable TCEP concentrations, we used the same motional model with variable component amplitudes. These amplitudes and their corresponding errors were normalized to unity and plotted vs. TCEP concentration using the data analysis software 'OriginPro2019'. The equivalence point of the titration curve was calculated based on the fitting formula:

$$F(x) = A1 + \frac{A2 - A1}{1 + 10^{(\text{Log}_x 0 - x)p}}$$

with  $A1$  = bottom asymptote,  $A2$  = top asymptote and  $p$  = Hill slope.

**Author Contributions:** Conceptualization, A.K.; Formal analysis, M.M.W., J.M.L., M.E., and A.K.; Funding acquisition, P.S. and A.K.; Investigation, M.M.W. and J.M.L.; Methodology, P.S., M.E., and A.K.; Supervision, P.S., M.E., and A.K.; Visualization, M.M.W. and J.M.L.; Writing—original draft, M.M.W. and A.K.; Writing—review and editing, J.M.L., P.S., M.E., and M.M.W. performed receptor mutagenesis, peptide synthesis, and functional characterization in cells. J.M.L. performed experiments with in vitro folded receptors and EPR measurements. P.S. supervised receptor expression and in vitro folding. M.E. supervised EPR spectroscopy and spectral fitting. A.K. initiated the project and supervised peptide synthesis and cellular experiments. All authors discussed and analyzed data. M.M.W. and A.K. wrote the manuscript with input from all co-authors. All authors have read and agreed to the published version of the manuscript.

**Funding:** Deutsche Forschungsgemeinschaft (DFG, the German Research Foundation), project number 421152132, SFB 1423, subproject A03 and B03.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data can be obtained from the authors upon reasonable request.

**Acknowledgments:** We thank Ronny Müller, Kristin Löbner, and Christina Dammann for their excellent technical assistance. This work was supported by Deutsche Forschungsgemeinschaft (DFG, the German Research Foundation), project number 421152132, SFB 1423, subproject A03 and B03.

**Conflicts of Interest:** The authors declare no conflict of interests.

## References

1. Sriram, K.; Insel, P.A. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? *Mol. Pharmacol.* **2018**, *93*, 251–258. [[CrossRef](#)] [[PubMed](#)]
2. Hauser, A.S.; Attwood, M.M.; Rask-Andersen, M.; Schiöth, H.B.; Gloriam, D.E. Trends in GPCR drug discovery: New agents, targets and indications. *Nat. Rev. Drug Discov.* **2017**, *16*, 829–842. [[CrossRef](#)] [[PubMed](#)]
3. Fredriksson, R.; Lagerström, M.C.; Lundin, L.-G.; Schiöth, H.B. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. *Mol. Pharmacol.* **2003**, *63*, 1256–1272. [[CrossRef](#)] [[PubMed](#)]
4. Kaiser, A.; Coin, I. Capturing Peptide-GPCR Interactions and Their Dynamics. *Molecules* **2020**, *25*, 4724. [[CrossRef](#)] [[PubMed](#)]
5. Elgeti, M.; Hubbell, W.L. DEER Analysis of GPCR Conformational Heterogeneity. *Biomolecules* **2021**, *11*, 778. [[CrossRef](#)]

6. Shimada, I.; Ueda, T.; Kofuku, Y.; Eddy, M.T.; Wüthrich, K. GPCR drug discovery: Integrating solution NMR data with crystal and cryo-EM structures. *Nat. Rev. Drug Discov.* **2019**, *18*, 59–82. [[CrossRef](#)]
7. Deganutti, G.; Liang, Y.-L.; Zhang, X.; Khoshouei, M.; Clydesdale, L.; Belousoff, M.J.; Venugopal, H.; Truong, T.T.; Glukhova, A.; Keller, A.N.; et al. Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation. *Nat. Commun.* **2022**, *13*, 92. [[CrossRef](#)]
8. Liang, Y.-L.; Belousoff, M.J.; Fletcher, M.M.; Zhang, X.; Khoshouei, M.; Deganutti, G.; Koole, C.; Furness, S.G.B.; Miller, L.J.; Hay, D.L.; et al. Structure and Dynamics of Adrenomedullin Receptors AM1 and AM2 Reveal Key Mechanisms in the Control of Receptor Phenotype by Receptor Activity-Modifying Proteins. *ACS Pharmacol. Transl. Sci.* **2020**, *3*, 263–284. [[CrossRef](#)]
9. Schihada, H.; Kowalski-Jahn, M.; Turku, A.; Schulte, G. Deconvolution of WNT-induced Frizzled conformational dynamics with fluorescent biosensors. *Biosens. Bioelectron.* **2021**, *177*, 112948. [[CrossRef](#)]
10. Schulte, G.; Wright, S.C. Frizzleds as GPCRs - More Conventional Than We Thought! *Trends Pharmacol. Sci.* **2018**, *39*, 828–842. [[CrossRef](#)]
11. Wingler, L.M.; Lefkowitz, R.J. Conformational Basis of G Protein-Coupled Receptor Signaling Versatility. *Trends Cell Biol.* **2020**, *30*, 736–747. [[CrossRef](#)]
12. Brian, K.K.; Xavier, D. Conformational complexity of G-protein-coupled receptors. *Trends Pharmacol. Sci.* **2007**, *28*, 397–406. [[CrossRef](#)]
13. Hauser, A.S.; Kooistra, A.J.; Munk, C.; Heydenreich, F.M.; Veprintsev, D.B.; Bouvier, M.; Babu, M.M.; Gloriam, D.E. GPCR activation mechanisms across classes and macro/microscales. *Nat. Struct. Mol. Biol.* **2021**, *28*, 879–888. [[CrossRef](#)]
14. Zhou, Q.; Yang, D.; Wu, M.; Guo, Y.; Guo, W.; Zhong, L.; Cai, X.; Dai, A.; Jang, W.; Shakhnovich, E.I.; et al. Common activation mechanism of class A GPCRs. *eLife* **2019**, *8*, e50279. [[CrossRef](#)]
15. Rader, A.J.; Anderson, G.; Isin, B.; Khorana, H.G.; Bahar, I.; Klein-Seetharaman, J. Identification of core amino acids stabilizing rhodopsin. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 7246–7251. [[CrossRef](#)]
16. Dohlman, H.G.; Caron, M.G.; DeBlasi, A.; Frielle, T.; Lefkowitz, R.J. Role of extracellular disulfide-bonded cysteines in the ligand binding function of the beta 2-adrenergic receptor. *Biochemistry* **1990**, *29*, 2335–2342. [[CrossRef](#)]
17. Noda, K.; Saad, Y.; Graham, R.M.; Karnik, S.S. The high affinity state of the beta 2-adrenergic receptor requires unique interaction between conserved and non-conserved extracellular loop cysteines. *J. Biol. Chem.* **1994**, *269*, 6743–6752. [[CrossRef](#)]
18. Elling, C.E.; Raffetseder, U.; Nielsen, S.M.; Schwartz, T.W. Disulfide bridge engineering in the tachykinin NK1 receptor. *Biochemistry* **2000**, *39*, 667–675. [[CrossRef](#)]
19. Cook, J.V.; Eidne, K.A. An intramolecular disulfide bond between conserved extracellular cysteines in the gonadotropin-releasing hormone receptor is essential for binding and activation. *Endocrinology* **1997**, *138*, 2800–2806. [[CrossRef](#)]
20. Zeng, F.Y.; Soldner, A.; Schöneberg, T.; Wess, J. Conserved extracellular cysteine pair in the M3 muscarinic acetylcholine receptor is essential for proper receptor cell surface localization but not for G protein coupling. *J. Neurochem.* **1999**, *72*, 2404–2414. [[CrossRef](#)]
21. Venkatakrisnan, A.J.; Deupi, X.; Lebon, G.; Tate, C.G.; Schertler, G.F.; Babu, M.M. Molecular signatures of G-protein-coupled receptors. *Nature* **2013**, *494*, 185–194. [[CrossRef](#)] [[PubMed](#)]
22. Yang, Z.; Han, S.; Keller, M.; Kaiser, A.; Bender, B.J.; Bosse, M.; Burkert, K.; Kögler, L.M.; Wifling, D.; Bernhardt, G.; et al. Structural basis of ligand binding modes at the neuropeptide Y Y1 receptor. *Nature* **2018**, *556*, 520–524. [[CrossRef](#)] [[PubMed](#)]
23. Tang, T.; Hartig, C.; Chen, Q.; Zhao, W.; Kaiser, A.; Zhang, X.; Zhang, H.; Qu, H.; Yi, C.; Ma, L. Structural basis for ligand recognition of the neuropeptide Y Y2 receptor. *Nat. Commun.* **2021**, *12*, 737. [[CrossRef](#)] [[PubMed](#)]
24. Tang, T.; Tan, Q.; Han, S.; Diemar, A.; Löbner, K.; Wang, H.; Schüß, C.; Behr, V.; Mörl, K.; Wang, M.; et al. Receptor-specific recognition of NPY peptides revealed by structures of NPY receptors. *Sci. Adv.* **2022**, *8*, eabm1232. [[CrossRef](#)]
25. Manglik, A.; Kruse, A.C.; Kobilka, T.S.; Thian, F.S.; Mathiesen, J.M.; Sunahara, R.K.; Pardo, L.; Weis, W.I.; Kobilka, B.K.; Granier, S. Crystal structure of the  $\mu$ -opioid receptor bound to a morphinan antagonist. *Nature* **2012**, *485*, 321–326. [[CrossRef](#)]
26. Wang, Y.; Zhuang, Y.; DiBerto, J.F.; Zhou, X.E.; Schmitz, G.P.; Yuan, Q.; Jain, M.K.; Liu, W.; Melcher, K.; Jiang, Y.; et al. Structures of the entire human opioid receptor family. *Cell* **2023**, *186*, 413–427.e17. [[CrossRef](#)]
27. Zhang, H.; Unal, H.; Gati, C.; Han, G.W.; Liu, W.; Zatsepin, N.A.; James, D.; Wang, D.; Nelson, G.; Weierstall, U.; et al. Structure of the Angiotensin receptor revealed by serial femtosecond crystallography. *Cell* **2015**, *161*, 833–844. [[CrossRef](#)]
28. Wingler, L.M.; Skiba, M.A.; McMahon, C.; Staus, D.P.; Kleinhenz, A.L.W.; Suomivuori, C.-M.; Latorraca, N.R.; Dror, R.O.; Lefkowitz, R.J.; Kruse, A.C. Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR. *Science* **2020**, *367*, 888–892. [[CrossRef](#)]
29. Shi, L.; Javitch, J.A. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. *Proc. Natl. Acad. Sci. USA* **2004**, *101*, 440–445. [[CrossRef](#)]
30. Unal, H.; Karnik, S.S. Domain coupling in GPCRs: The engine for induced conformational changes. *Trends Pharmacol. Sci.* **2012**, *33*, 79–88. [[CrossRef](#)]
31. Woolley, M.J.; Conner, A.C. Understanding the common themes and diverse roles of the second extracellular loop (ECL2) of the GPCR super-family. *Mol. Cell. Endocrinol.* **2017**, *449*, 3–11. [[CrossRef](#)]
32. Yi, M.; Li, H.; Wu, Z.; Yan, J.; Liu, Q.; Ou, C.; Chen, M. A Promising Therapeutic Target for Metabolic Diseases: Neuropeptide Y Receptors in Humans. *Cell. Physiol. Biochem.* **2018**, *45*, 88–107. [[CrossRef](#)]
33. Zhang, Y.; Liu, C.-Y.; Chen, W.-C.; Shi, Y.-C.; Wang, C.-M.; Lin, S.; He, H.-F. Regulation of neuropeptide Y in body microenvironments and its potential application in therapies: A review. *Cell Biosci.* **2021**, *11*, 151. [[CrossRef](#)]

34. Kostenis, E.; Waelbroeck, M.; Milligan, G. Techniques: Promiscuous Galpha proteins in basic research and drug discovery. *Trends Pharmacol. Sci.* **2005**, *26*, 595–602. [[CrossRef](#)]
35. Swanson, D.M.; Wong, V.D.; Jablonowski, J.A.; Shah, C.; Rudolph, D.A.; Dvorak, C.A.; Seierstad, M.; Dvorak, L.K.; Morton, K.; Nepomuceno, D.; et al. The discovery and synthesis of JNJ 31020028, a small molecule antagonist of the Neuropeptide Y Y<sub>2</sub> receptor. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 5552–5556. [[CrossRef](#)]
36. Hubbell, W.L.; Cafiso, D.S.; Altenbach, C. Identifying conformational changes with site-directed spin labeling. *Nat. Struct. Biol.* **2000**, *7*, 735–739. [[CrossRef](#)]
37. Torricella, F.; Pierro, A.; Mileo, E.; Belle, V.; Bonucci, A. Nitroxide spin labels and EPR spectroscopy: A powerful association for protein dynamics studies. *Biochim. Biophys. Acta Proteins Proteom.* **2021**, *1869*, 140653. [[CrossRef](#)]
38. Witte, K.; Kaiser, A.; Schmidt, P.; Splith, V.; Thomas, L.; Berndt, S.; Huster, D.; Beck-Sickinger, A.G. Oxidative in vitro folding of a cysteine deficient variant of the G protein-coupled neuropeptide Y receptor type 2 improves stability at high concentration. *Biol. Chem.* **2013**, *394*, 1045–1056. [[CrossRef](#)]
39. Laugwitz, J.M.; Haeri, H.H.; Kaiser, A.; Krug, U.; Hinderberger, D.; Beck-Sickinger, A.G.; Schmidt, P. Probing the Y<sub>2</sub> Receptor on Transmembrane, Intra- and Extra-Cellular Sites for EPR Measurements. *Molecules* **2020**, *25*, 4143. [[CrossRef](#)]
40. Krug, U.; Gloge, A.; Schmidt, P.; Becker-Baldus, J.; Bernhard, F.; Kaiser, A.; Montag, C.; Gauglitz, M.; Vishnivetskiy, S.A.; Gurevich, V.V.; et al. The Conformational Equilibrium of the Neuropeptide Y<sub>2</sub> Receptor in Bilayer Membranes. *Angew. Chem. Int. Ed Engl.* **2020**, *59*, 23854–23861. [[CrossRef](#)]
41. Schmidt, P.; Vogel, A.; Schwarze, B.; Seufert, F.; Licha, K.; Wycisk, V.; Kilian, W.; Hildebrand, P.W.; Mitschang, L. Towards Probing Conformational States of Y<sub>2</sub> Receptor Using Hyperpolarized <sup>129</sup>Xe NMR. *Molecules* **2023**, *28*, 1424. [[CrossRef](#)] [[PubMed](#)]
42. Wanka, L.; Babilon, S.; Kaiser, A.; Mörl, K.; Beck-Sickinger, A.G. Different mode of arrestin-3 binding at the human Y<sub>1</sub> and Y<sub>2</sub> receptor. *Cell. Signal.* **2018**, *50*, 58–71. [[CrossRef](#)] [[PubMed](#)]
43. Zhang, P.; Johnson, P.S.; Zöllner, C.; Wang, W.; Wang, Z.; Montes, A.E.; Seidleck, B.K.; Blaschak, C.J.; Surratt, C.K. Mutation of human mu opioid receptor extracellular "disulfide cysteine" residues alters ligand binding but does not prevent receptor targeting to the cell plasma membrane. *Brain Res. Mol. Brain Res.* **1999**, *72*, 195–204. [[CrossRef](#)] [[PubMed](#)]
44. Sumita, C.; Annette, R.; Alan, R.; Gintzler. Biochemical demonstration of mu-opioid receptor association with G<sub>s</sub>α: Enhancement following morphine exposure. *Brain Res. Mol. Brain Res.* **2005**, *135*, 217–224. [[CrossRef](#)]
45. Shen, K.F.; Crain, S.M. Cholera toxin-A subunit blocks opioid excitatory effects on sensory neuron action potentials indicating mediation by G<sub>s</sub>-linked opioid receptors. *Brain Res.* **1990**, *525*, 225–231. [[CrossRef](#)]
46. Avidor-Reiss, T.; Bayewitch, M.; Levy, R.; Matus-Leibovitch, N.; Nevo, I.; Vogel, Z. Adenylyl cyclase supersensitization in mu-opioid receptor-transfected Chinese hamster ovary cells following chronic opioid treatment. *J. Biol. Chem.* **1995**, *270*, 29732–29738. [[CrossRef](#)]
47. Nicoli, A.; Dunkel, A.; Giorgino, T.; Graaf, C.d.; Di Pizio, A. Classification Model for the Second Extracellular Loop of Class A GPCRs. *J. Chem. Inf. Model.* **2022**, *62*, 511–522. [[CrossRef](#)]
48. Wheatley, M.; Wootten, D.; Conner, M.T.; Simms, J.; Kendrick, R.; Logan, R.T.; Poyner, D.R.; Barwell, J. Lifting the lid on GPCRs: The role of extracellular loops. *Br. J. Pharmacol.* **2012**, *165*, 1688–1703. [[CrossRef](#)]
49. Wootten, D.; Simms, J.; Miller, L.J.; Christopoulos, A.; Sexton, P.M. Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 5211–5216. [[CrossRef](#)]
50. Mann, R.J.; Al-Sabah, S.; Maturana, R.L.d.; Sinfield, J.K.; Donnelly, D. Functional coupling of Cys-226 and Cys-296 in the glucagon-like peptide-1 (GLP-1) receptor indicates a disulfide bond that is close to the activation pocket. *Peptides* **2010**, *31*, 2289–2293. [[CrossRef](#)]
51. Oakley, R.H.; Laporte, S.A.; Holt, J.A.; Caron, M.G.; Barak, L.S. Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. *J. Biol. Chem.* **2000**, *275*, 17201–17210. [[CrossRef](#)]
52. Aydin, Y.; Coin, I. Biochemical insights into structure and function of arrestins. *FEBS J.* **2021**, *288*, 2529–2549. [[CrossRef](#)]
53. Wanka, L.; Behr, V.; Beck-Sickinger, A.G. Arrestin-dependent internalization of rhodopsin-like G protein-coupled receptors. *Biol. Chem.* **2022**, *403*, 133–149. [[CrossRef](#)]
54. Wacker, D.; Wang, S.; McCorvy, J.D.; Betz, R.M.; Venkatakrishnan, A.J.; Levit, A.; Lansu, K.; Schools, Z.L.; Che, T.; Nichols, D.E.; et al. Crystal Structure of an LSD-Bound Human Serotonin Receptor. *Cell* **2017**, *168*, 377–389.e12. [[CrossRef](#)]
55. Rath, P.; Bovee-Geurts, P.H.; DeGrip, W.J.; Rothschild, K.J. Photoactivation of rhodopsin involves alterations in cysteine side chains: Detection of an S-H band in the Meta I–Meta II FTIR difference spectrum. *Biophys. J.* **1994**, *66*, 2085–2091. [[CrossRef](#)]
56. Parthier, C.; Reedtz-Runge, S.; Rudolph, R.; Stubbs, M.T. Passing the baton in class B GPCRs: Peptide hormone activation via helix induction? *Trends Biochem. Sci.* **2009**, *34*, 303–310. [[CrossRef](#)]
57. Liang, Y.-L.; Belousoff, M.J.; Zhao, P.; Koole, C.; Fletcher, M.M.; Truong, T.T.; Julita, V.; Christopoulos, G.; Xu, H.E.; Zhang, Y.; et al. Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation. *Mol. Cell* **2020**, *77*, 656–668.e5. [[CrossRef](#)]
58. Wolf, S.; Grünewald, S. Sequence, structure and ligand binding evolution of rhodopsin-like G protein-coupled receptors: A crystal structure-based phylogenetic analysis. *PLoS ONE* **2015**, *10*, e0123533. [[CrossRef](#)]
59. Duan, J.; Shen, D.-D.; Zhou, X.E.; Bi, P.; Liu, Q.-F.; Tan, Y.-X.; Zhuang, Y.-W.; Zhang, H.-B.; Xu, P.-Y.; Huang, S.-J.; et al. Cryo-EM structure of an activated VIP1 receptor-G protein complex revealed by a NanoBiT tethering strategy. *Nat. Commun.* **2020**, *11*, 4121. [[CrossRef](#)]



60. Wang, X.; Cheng, X.; Zhao, L.; Wang, Y.; Ye, C.; Zou, X.; Dai, A.; Cong, Z.; Chen, J.; Zhou, Q.; et al. Molecular insights into differentiated ligand recognition of the human parathyroid hormone receptor 2. *Proc. Natl. Acad. Sci. USA* **2021**, *118*. [[CrossRef](#)]
61. Koole, C.; Wootten, D.; Simms, J.; Savage, E.E.; Miller, L.J.; Christopoulos, A.; Sexton, P.M. Second extracellular loop of human glucagon-like peptide-1 receptor (GLP-1R) differentially regulates orthosteric but not allosteric agonist binding and function. *J. Biol. Chem.* **2012**, *287*, 3659–3673. [[CrossRef](#)] [[PubMed](#)]
62. Seidel, L.; Zarzycka, B.; Zaidi, S.A.; Katritch, V.; Coin, I. Structural insight into the activation of a class B G-protein-coupled receptor by peptide hormones in live human cells. *eLife* **2017**, *6*, e27711. [[CrossRef](#)] [[PubMed](#)]
63. Gkoutelias, K.; Tselios, T.; Venihaki, M.; Deraos, G.; Lazaridis, I.; Rassouli, O.; Gravanis, A.; Liapakis, G. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding. *Mol. Pharmacol.* **2009**, *75*, 793–800. [[CrossRef](#)]
64. Pal, K.; Melcher, K.; Xu, H.E. Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors. *Acta Pharmacol. Sin.* **2012**, *33*, 300–311. [[CrossRef](#)]
65. Coin, I.; Katritch, V.; Sun, T.; Xiang, Z.; Siu, F.Y.; Beyermann, M.; Stevens, R.C.; Wang, L. Genetically encoded chemical probes in cells reveal the binding path of urocortin-I to CRF class B GPCR. *Cell* **2013**, *155*, 1258–1269. [[CrossRef](#)] [[PubMed](#)]
66. Zhang, H.; Qiao, A.; Yang, L.; van Eps, N.; Frederiksen, K.S.; Yang, D.; Dai, A.; Cai, X.; Zhang, H.; Yi, C.; et al. Structure of the glucagon receptor in complex with a glucagon analogue. *Nature* **2018**, *553*, 106–110. [[CrossRef](#)]
67. Graaf, C.d.; Song, G.; Cao, C.; Zhao, Q.; Wang, M.-W.; Wu, B.; Stevens, R.C. Extending the Structural View of Class B GPCRs. *Trends Biochem. Sci.* **2017**, *42*, 946–960. [[CrossRef](#)]
68. Liu, H.; Naismith, J.H. An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. *BMC Biotechnol.* **2008**, *8*, 91. [[CrossRef](#)]
69. Mäde, V.; Bellmann-Sickert, K.; Kaiser, A.; Meiler, J.; Beck-Sickinger, A.G. Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues. *ChemMedChem* **2014**, *9*, 2463–2474. [[CrossRef](#)]
70. Kaiser, A.; Beck-Sickinger, A.G.; Zhao, Q.; Wu, B. IP accumulation assay. *BIO-PROTOCOL* **2022**. [[CrossRef](#)]
71. Wolf, P.; Mohr, A.; Gavins, G.; Behr, V.; Mörl, K.; Seitz, O.; Beck-Sickinger, A.G. Orthogonal Peptide-Templated Labeling Elucidates Lateral ETA R/ETB R Proximity and Reveals Altered Downstream Signaling. *Chembiochem* **2022**, *23*, e202100340. [[CrossRef](#)]
72. Rudolf, K.; Eberlein, W.; Engel, W.; Wieland, H.A.; Willim, K.D.; Entzeroth, M.; Wienen, W.; Beck-Sickinger, A.G.; Doods, H.N. The first highly potent and selective non-peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. *Eur. J. Pharmacol.* **1994**, *271*, R11–R13. [[CrossRef](#)]
73. Shoblock, J.R.; Welty, N.; Nepomuceno, D.; Lord, B.; Aluisio, L.; Fraser, I.; Motley, S.T.; Sutton, S.W.; Morton, K.; Galici, R.; et al. In vitro and in vivo characterization of JNJ-31020028 (N-(4-(4-(2-(diethylamino)-2-oxo-1-phenylethylpiperazin-1-yl)-3-fluorophenyl)-2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide Y Y(2) receptor. *Psychopharmacology* **2010**, *208*, 265–277. [[CrossRef](#)]
74. Schmidt, P.; Bender, B.J.; Kaiser, A.; Gulati, K.; Scheidt, H.A.; Hamm, H.E.; Meiler, J.; Beck-Sickinger, A.G.; Huster, D. Improved in Vitro Folding of the Y2 G Protein-Coupled Receptor into Bicelles. *Front. Mol. Biosci.* **2017**, *4*, 100. [[CrossRef](#)]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.